Compass Therapeutics, Inc. (CMPX) Balance Sheet
As of 2026-06-30 (10-Q), Compass Therapeutics, Inc. (CMPX) reported total assets of $190.2M, total liabilities of $24.1M and shareholders' equity of $166.0M, according to EquiReason's reading of its SEC filings. Cash and equivalents: $35.5M.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
CMPXCompass Therapeutics, Inc.Follow CMPX — free
—
Price chart with a free account
- Market cap
- 137.0M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 11 Nov, in 18 days
| Line | FY2019 Mar 19 | FY2020 Mar 20 | FY2020 Dec 20 | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | Latest Jun 26 | Trend |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 0.0 | 0.0 | 47.1 | 144.5 | 34.9 | 24.2 | 43.5 | 30.6 | 35.5 | |
| Short-term investments | — | — | — | 0.0 | 151.7 | 128.2 | 83.2 | 178.3 | 144.4 | |
| Current assets | 0.0 | 0.0 | 50.2 | 147.1 | 194.8 | 153.9 | 132.8 | 209.8 | 180.9 | |
| Total assets | 0.0 | 0.0 | 51.9 | 153.8 | 199.6 | 156.9 | 140.4 | 219.6 | 190.2 | |
| Current liabilities | 0.1 | 0.1 | 10.1 | 10.6 | 16.2 | 7.8 | 8.9 | 14.0 | 16.1 | |
| Long-term debt | — | — | 1.9 | 0.0 | — | — | — | — | — | |
| Short-term debt | — | — | 7.5 | 0.0 | — | — | — | — | — | |
| Total liabilities | 0.1 | 0.1 | 12.0 | 13.7 | 18.0 | 8.3 | 15.2 | 22.8 | 24.1 | |
| Shareholders' equity | -95.3 | -124.8 | 39.9 | 140.1 | 181.6 | 148.5 | 125.2 | 196.8 | 166.0 |
USD millions · SEC XBRL
Compass Therapeutics, Inc. — questions
- How much cash does Compass Therapeutics, Inc. have?
- $35.5M in cash and cash equivalents as of 2026-06-30.
- What are Compass Therapeutics, Inc.'s total assets?
- $190.2M as of 2026-06-30.
- What is Compass Therapeutics, Inc.'s shareholders' equity?
- $166.0M as of 2026-06-30.
Every figure on this page comes from Compass Therapeutics, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.